{"entity":{"id":"nct05254171","kind":"trial","name":"Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer","aka":["ASPIRE"],"tldr":"A phase 2/3 trial testing Ivospemin in pancreatic ductal adenocarcinoma, now recruiting.","summary":"Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer is a phase 2/3 interventional study registered as NCT05254171, led by Panbela Therapeutics, and recruiting on the registry. Official title: A Randomised, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma. Planned enrolment is 600 participants (estimated). The study started in 2022-08-08 and primary completion is expected in 2026-08-29. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05254171","url":"https://clinicaltrials.gov/study/NCT05254171"}],"tags":["ctgov-ingest"],"related":[],"cancers":["pancreatic","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["ivospemin"],"companies":["panbela-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05254171","phase":"2/3","setting":"A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma","sponsor":"Panbela Therapeutics","participation":[{"nct":"NCT05254171","source":"https://clinicaltrials.gov/study/NCT05254171","fetchedAt":"2026-10-07T16:53:38.157Z","studySha256":"ee52ccb73e94b42dc203551d3c1da4467abe87fc69e4a347b356df938202bdd5","overallStatus":"RECRUITING","lastUpdatePosted":"2024-11-06","leadSponsor":"Panbela Therapeutics, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":600,"enrolmentType":"ESTIMATED","siteCount":93,"recruitingSiteCount":77,"countries":["Australia","Austria","Belgium","France","Germany","Italy","South Korea","Spain","United Kingdom","United States"]}],"started":"2022-08-08","startedType":"actual","enrolled":600,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05254171/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"ivospemin","kind":"drug","name":"Ivospemin","route":"/drugs/ivospemin/"}],"company":[{"id":"panbela-therapeutics","kind":"company","name":"Panbela Therapeutics","route":"/companies/panbela-therapeutics/"}]}}